...
首页> 外文期刊>Journal of Medicinal Chemistry >Array-Based Structure and Gene Expression Relationship Study of Antitumor Sulfonamides Including N-(2-((4-Hydroxyphenyl)amino)-3-pyridinyl)-4-methoxybenzenesulfonamide and N-(3-Chloro-7-indolyl)-1,4-benzenedisulfonamide.
【24h】

Array-Based Structure and Gene Expression Relationship Study of Antitumor Sulfonamides Including N-(2-((4-Hydroxyphenyl)amino)-3-pyridinyl)-4-methoxybenzenesulfonamide and N-(3-Chloro-7-indolyl)-1,4-benzenedisulfonamide.

机译:N-(2-((4-羟基苯基)氨基)-3-吡啶基)-4-甲氧基苯磺酰胺和N-(3-氯-7-吲哚基)-1的抗肿瘤磺酰胺的基于阵列的结构和基因表达关系的研究4-苯二磺酰胺。

获取原文
获取原文并翻译 | 示例

摘要

Compounds from sulfonamide-focused libraries have been evaluated in cell-based antitumor screens using the COMPARE analysis with a panel of 39 human cancer cell lines and flow cytometric cell cycle analysis. Thus far, 2 (N-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenzenesulfonamide (E7010)) and 3 (N-(3-chloro-7-indolyl)-1,4-benzenedisulfonamide (E7070)) have been selected from the collections as potent cell cycle inhibitors, which have progressed to clinical trials. Compound 2 is an orally active antimitotic agent disrupting tubulin polymerization, whereas compound 3 belongs to a novel class of antiproliferative agents causing a decrease in the S phase fraction along with G1 and/or G2 accumulation in various cancer cell lines. Because both compounds exhibited preliminary clinical activities in the phase I setting, we decided to examine further this series of oncolytic small molecules, particularly by using high-density oligonucleotide microarray analysis. The array data have enabled us to characterize these two classes of antitumor sulfonamides on the basis of gene expression changes, illuminating the essential pharmacophore structure and drug-sensitive cellular pathways for each class. Moreover, the dual character of 5 (N-(3-chloro-7-indolyl)-4-methoxybenzenesulfonamide (ER-67880)), resembling both 2 and 3, was revealed by array-based transcription profiling, though the 3-type profile of this molecule had not been apparent in the cell-based phenotypic screens. These results provide an example of the utility of structure and gene expression relationship studies in medicinal genomics.
机译:使用COMPARE分析(包含39种人类癌细胞系)和流式细胞术细胞周期分析,已在基于细胞的抗肿瘤筛选中评估了以磺酰胺为重点的库中的化合物。到目前为止,2(N- [2-[(4-羟基苯基)氨基] -3-吡啶基] -4-甲氧基苯磺酰胺(E7010))和3(N-(3-氯-7-吲哚基)-1,4-苯二磺酰胺(E7070)已被选为有效的细胞周期抑制剂,已进入临床试验。化合物2是破坏微管蛋白聚合的口服活性抗有丝分裂剂,而化合物3属于一类新型的抗增殖剂,其引起S期分数的下降以及G1和/或G2在各种癌细胞系中的积累。由于这两种化合物在I期临床试验中均显示出初步的临床活性,因此我们决定进一步检查这一系列溶瘤小分子,特别是通过使用高密度寡核苷酸微阵列分析。阵列数据使我们能够根据基因表达变化来表征这两类抗肿瘤磺酰胺,阐明了每一类的基本药效基团结构和药物敏感性细胞途径。此外,尽管基于3型,但通过基于阵列的转录谱揭示了5(N-(3-氯-7-吲哚基)-4-甲氧基苯磺酰胺(ER-67880))的双重特征,类似于2和3。在基于细胞的表型筛选中,该分子的分布图并不明显。这些结果提供了一个结构和基因表达关系研究在医学基因组学中的应用实例。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号